{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T23:22:05Z","timestamp":1783207325497,"version":"3.54.6"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Merck KGaA, Darmstadt, Germany"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>STUDY QUESTION<\/jats:title>\n                  <jats:p>Can the Poor Responder Outcome Prediction (PROsPeR) score identify live birth outcomes in subpopulations of patients with poor ovarian response (POR) defined according to the ESHRE Bologna criteria (female age, anti-M\u00fcllerian hormone (AMH), number of oocytes retrieved during the previous cycle (PNO) after treatment with originator recombinant human follitropin alfa?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY ANSWER<\/jats:title>\n                  <jats:p>The PROsPeR score discriminated the probability of live birth in patients with POR using observational data with fair discrimination (AUC \u2245 70%) and calibration, and the AUC losing less than 5% precision compared with a model developed using the observational data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                  <jats:p>Although scoring systems for the likelihood of live birth after ART have been developed, their accuracy may be insufficient, as they have generally been developed in the general population with infertility and were not validated for patients with POR. The PROsPeR score was developed using data from the follitropin alfa (GONAL-f; Merck KGaA, Darmstadt, Germany) arm of the Efficacy and Safety of Pergoveris in Assisted Reproductive Technology (ESPART) randomized controlled trial (RCT) and classifies women with POR as mild, moderate or severe, based upon three variables: female age, serum AMH level and number of oocytes retrieved during the previous cycle (PNO).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                  <jats:p>The external validation of the PROsPeR score was completed using data derived from eight different centres in France. In addition, the follitropin alfa data from the ESPART RCT, originally used to develop the PROsPeR score, were used as reference cohort. The external validation of the PROsPeR score l was assessed using AUC. A predetermined non-inferiority limit of 0.10 compared with a reference sample and calibration (Hosmer\u2013Lemeshow test) were the two conditions required for evaluation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                  <jats:p>The observational cohort included data from 8085 ART treatment cycles performed with follitropin alfa in patients with POR defined according to the ESHRE Bologna criteria (17.6% of the initial data set). The ESPART cohort included 477 ART treatment cycles with ovarian stimulation performed with follitropin alfa in patients with POR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                  <jats:p>The external validation of the PROsPeR score to identify subpopulations of women with POR with different live birth outcomes was shown in the observational cohort (AUC\u2009=\u20090.688; 95% CI: 0.662, 0.714) compared with the ESPART cohort (AUC = 0.695; 95% CI: 0.623, 0.767). The AUC difference was \u22120.0074 (95% CI: \u22120.083, 0.0689). This provided evidence, with 97.5% one-sided confidence, that there was a maximum estimated loss of 8.4% in discrimination between the observational cohort and the ESPART cohort, which was below the predetermined margin of 10%. The Hosmer\u2013Lemeshow test did not reject the calibration when comparing observed and predicted data (Hosmer\u2013Lemeshow test = 1.266688; P\u2009=\u20090.260).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                  <jats:p>The study was based on secondary use of data that had not been collected specifically for the analysis reported here and the number of characteristics used to classify women with POR was limited to the available data. The data were from a limited number of ART centres in a single country, which may present a bias risk; however, baseline patient data were similar to other POR studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                  <jats:p>This evaluation of the PROsPeR score using observational data supports the notion that the likelihood of live birth may be calculated with reasonable precision using three readily available pieces of data (female age, serum AMH and PNO). The PROsPeR score has potential to be used to discriminate expected probability of live birth according to the degree of POR (mild, moderate, severe) after treatment with follitropin alfa, enabling comparison of performance at one centre over time and the comparison between centres.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                  <jats:p>This analysis was funded by Merck KGaA, Darmstadt, Germany. P.L. received grants from Merck KGaA, outside of the submitted work. N.M. reports grants, personal fees and non-financial support from Merck KGaA outside the submitted work. T.D.H. is Vice President and Head of Global Medical Affairs Fertility, Research and Development at Merck KGaA, Darmstadt, Germany. P.A. has received personal fees from Merck KGaA, Darmstadt, Germany, outside the submitted work. C.R. has received grants and personal fees from Gedeon Richter and Merck Serono S.A.S., France, an affiliate of Merck KGaA, Darmstadt, Germany, outside the submitted work. P.S. reports congress support from Merck Serono S.A.S., France (an affiliate of Merck KGaA, Darmstadt, Germany), Gedeon Richter, TEVA and MDS outside the submitted work. C.A., J.P., G.P. and R.W. declare no conflict of interest.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                  <jats:p>N\/A<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/humrep\/deab050","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T15:29:32Z","timestamp":1613575772000},"page":"1600-1610","source":"Crossref","is-referenced-by-count":5,"title":["A large observational data study supporting the PROsPeR score classification in poor ovarian responders according to live birth outcome"],"prefix":"10.1093","volume":"36","author":[{"given":"P","family":"Lehert","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Melbourne University, Melbourne, Australia"},{"name":"Faculty of Economics, Louvain University, Louvain, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Arvis","sequence":"additional","affiliation":[{"name":"La Sagesse, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Avril","sequence":"additional","affiliation":[{"name":"Clinique Mathilde, 76100 Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Massin","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Intercommunal de Creteil, 94000 Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Parinaud","sequence":"additional","affiliation":[{"name":"H\u00f4pital Paule de Viguier, 31000 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Porcu","sequence":"additional","affiliation":[{"name":"IMR, 13008 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Rongi\u00e8res","sequence":"additional","affiliation":[{"name":"CMCO, 67300 Schiltigheim, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Sagot","sequence":"additional","affiliation":[{"name":"CHU Dijon, 21079 Dijon Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Wainer","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de Poissy, 78303 Poissy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"D\u2019Hooghe","sequence":"additional","affiliation":[{"name":"Global Medical Affairs Fertility, R&D Biopharma, Merck Healthcare KGaA, Darmstadt, Germany"},{"name":"Department of Development and Regeneration, Biomedical Sciences Group, KU Leuven (University of Leuven), Belgium"},{"name":"Department of Obstetrics and Gynecology, Yale University, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,16]]},"reference":[{"key":"2021070807482785600_deab050-B2","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1093\/humrep\/des283","article-title":"Simple adaptations to the Templeton model for IVF outcome prediction make it current and clinically useful","volume":"27","author":"Arvis","year":"2012","journal-title":"Hum Reprod"},{"key":"2021070807482785600_deab050-B3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.rbmo.2017.03.009","article-title":"Live birth rates in various subgroups of poor ovarian responders fulfilling the Bologna criteria","volume":"34","author":"Bozdag","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"2021070807482785600_deab050-B4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/humrep\/deu319","article-title":"Retrospective evaluation of prognosis and cost-effectiveness of IVF in poor responders according to the Bologna criteria","volume":"30","author":"Busnelli","year":"2015","journal-title":"Hum Reprod"},{"key":"2021070807482785600_deab050-B5","first-page":"89","article-title":"Prognosis and cost-effectiveness of IVF in poor responders according to the Bologna Criteria","volume":"70","author":"Busnelli","year":"2018","journal-title":"Minerva Ginecol"},{"key":"2021070807482785600_deab050-B6","doi-asserted-by":"crossref","first-page":"e0119149","DOI":"10.1371\/journal.pone.0119149","article-title":"Live birth and cumulative live birth rates in expected poor ovarian responders defined by the Bologna criteria following IVF\/ICSI treatment","volume":"10","author":"Chai","year":"2015","journal-title":"PLoS One"},{"key":"2021070807482785600_deab050-B7","first-page":"539","article-title":"The comparison of microdose flare-up and multiple dose antagonist protocols based on hCG day estradiol (E2), progesterone (P) and P\/E2 ratio among poor responder patients in ICSI-ET cycles","volume":"19","author":"Cicek","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2021070807482785600_deab050-B8","author":"Commission Nationale de l'Informatique et des Libert\u00e9s","year":"2016"},{"key":"2021070807482785600_deab050-B9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1373\/clinchem.2007.096529","article-title":"Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve","volume":"54","author":"Cook","year":"2008","journal-title":"Clin Chem"},{"key":"2021070807482785600_deab050-B10","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/humrep\/dep109","article-title":"Evaluating prediction models in reproductive medicine","volume":"24","author":"Coppus","year":"2009","journal-title":"Hum Reprod"},{"key":"2021070807482785600_deab050-B11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"2021070807482785600_deab050-B12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.mefs.2018.06.002","article-title":"Outcome of assisted reproductive technology in different subgroups of poor ovarian responders fulfilling the POSEIDON criteria","volume":"23","author":"Eftekhar","year":"2018","journal-title":"Middle East Fertil Soc J"},{"key":"2021070807482785600_deab050-B13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fendo.2018.00461","article-title":"Defining low prognosis patients undergoing assisted reproductive technology: POSEIDON criteria-the why","volume":"9","author":"Esteves","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2021070807482785600_deab050-B14","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/humrep\/der092","article-title":"ESHRE consensus on the definition of \u2018poor response\u2019 to ovarian stimulation for in vitro fertilization: the Bologna criteria","volume":"26","author":"Ferraretti","year":"2011","journal-title":"Hum Reprod"},{"key":"2021070807482785600_deab050-B11115","doi-asserted-by":"crossref","DOI":"10.1177\/2158244016668220","article-title":"Multiple imputation of multilevel missing data: an introduction to the R package pan","volume":"6","author":"Grund","year":"2016","journal-title":"SAGE Open"},{"key":"2021070807482785600_deab050-B15","volume-title":"Applied Logistic Regression","author":"Hosmer","year":"2005","edition":"2 edn."},{"key":"2021070807482785600_deab050-B16","first-page":"544","article-title":"Efficacy and safety of follitropin alfa\/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders","volume":"32","author":"Humaidan","year":"2017","journal-title":"Hum Reprod Open"},{"key":"2021070807482785600_deab050-B17","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMsb1503104","article-title":"Precision medicine\u2013personalized, problematic, and promising","volume":"372","author":"Jameson","year":"2015","journal-title":"N Engl J Med"},{"key":"2021070807482785600_deab050-B63691678","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/humupd\/dmt037","article-title":"Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice","volume":"20","author":"La Marca","year":"2014","journal-title":"Hum Reprod Update"},{"key":"2021070807482785600_deab050-B18","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10815-015-0476-4","article-title":"Live birth rates in the different combinations of the Bologna criteria poor ovarian responders: a validation study","volume":"32","author":"La Marca","year":"2015","journal-title":"J Assist Reprod Genet"},{"key":"2021070807482785600_deab050-B19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.rbmo.2018.03.013","article-title":"Predicting live birth for poor ovarian responders: the PROsPeR concept","volume":"37","author":"Lehert","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"2021070807482785600_deab050-B20","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/humrep\/dey263","article-title":"Predicting the cumulative chance of live birth over multiple complete cycles of in vitro fertilization: an external validation study","volume":"33","author":"Leijdekkers","year":"2018","journal-title":"Hum Reprod"},{"key":"2021070807482785600_deab050-B21","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/humrep\/dez184","article-title":"Individualized ovarian stimulation in IVF\/ICSI treatment: it is time to stop using high FSH doses in predicted low responders","volume":"35","author":"Leijdekkers","year":"2020","journal-title":"Hum Reprod"},{"key":"2021070807482785600_deab050-B22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/humrep\/dep358","article-title":"Can differences in IVF success rates between centres be explained by patient characteristics and sample size?","volume":"25","author":"Lintsen","year":"2010","journal-title":"Hum Reprod"},{"key":"2021070807482785600_deab050-B23","doi-asserted-by":"crossref","first-page":"i5735","DOI":"10.1136\/bmj.i5735","article-title":"Predicting the chances of a live birth after one or more complete cycles of in vitro fertilisation: population based study of linked cycle data from 113 873 women","volume":"355","author":"McLernon","year":"2016","journal-title":"BMJ"},{"key":"2021070807482785600_deab050-B24","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.fertnstert.2018.09.021","article-title":"Oocyte donation: insights gleaned and future challenges","volume":"110","author":"Melnick","year":"2018","journal-title":"Fertil Steril"},{"key":"2021070807482785600_deab050-B25","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.fertnstert.2018.04.037","article-title":"Personalized ovarian stimulation for assisted reproductive technology: study design considerations to move from hype to added value for patients","volume":"109","author":"Mol","year":"2018","journal-title":"Fertil Steril"},{"key":"2021070807482785600_deab050-B26","doi-asserted-by":"crossref","first-page":"e1000386","DOI":"10.1371\/journal.pmed.1000386","article-title":"Predicting live birth, preterm delivery, and low birth weight in infants born from in vitro fertilisation: a prospective study of 144,018 treatment cycles","volume":"8","author":"Nelson","year":"2011","journal-title":"PLoS Med"},{"key":"2021070807482785600_deab050-B27","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1373\/clinchem.2004.031823","article-title":"ROC curves in clinical chemistry: uses, misuses, and possible solutions","volume":"50","author":"Obuchowski","year":"2004","journal-title":"Clin Chem"},{"key":"2021070807482785600_deab050-B28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.repbio.2017.01.006","article-title":"GnRH antagonist and letrozole co-treatment in diminished ovarian reserve patients: a proof-of-concept study","volume":"17","author":"Olgan","year":"2017","journal-title":"Reprod Biol"},{"key":"2021070807482785600_deab050-B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/humupd\/dmr037","article-title":"The poor responder in IVF: Is the prognosis always poor?: a systematic review","volume":"18","author":"Oudendijk","year":"2012","journal-title":"Hum Reprod Update"},{"key":"2021070807482785600_deab050-B30","doi-asserted-by":"crossref","first-page":"e0201824","DOI":"10.1371\/journal.pone.0201824","article-title":"Early stop of progesterone supplementation after confirmation of pregnancy in IVF\/ICSI fresh embryo transfer cycles of poor responders does not affect pregnancy outcome","volume":"13","author":"Pan","year":"2018","journal-title":"PLoS One"},{"key":"2021070807482785600_deab050-B31","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/humrep\/deu135","article-title":"Implementing the ESHRE \u2018poor responder\u2019 criteria in research studies: methodological implications","volume":"29","author":"Papathanasiou","year":"2014","journal-title":"Hum Reprod"},{"key":"2021070807482785600_deab050-B16696889","first-page":"i459","article-title":"A first study in France","volume":"31","author":"Parneix","year":"2016","journal-title":"Human Reprod"},{"key":"2021070807482785600_deab050-B6696889","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/sim.2929","article-title":"Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond","volume":"27","author":"Pencina","year":"2008","journal-title":"Statist Med"},{"key":"2021070807482785600_deab050-B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7827-11-1","article-title":"Predicting live birth chances for women with multiple consecutive failing IVF cycles: a simple and accurate prediction for routine medical practice","volume":"11","author":"Porcu","year":"2013","journal-title":"Reprod Biol Endocrinol"},{"key":"2021070807482785600_deab050-B33","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.fertnstert.2016.02.005","article-title":"A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept","volume":"105","author":"Poseidon","year":"2016","journal-title":"Fertil Steril"},{"key":"2021070807482785600_deab050-B34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/humrep\/dez258","article-title":"A systematic review of the quality of clinical prediction models in in vitro fertilisation","volume":"35","author":"Ratna","year":"2020","journal-title":"Hum Reprod"},{"key":"2021070807482785600_deab050-B35","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"2021070807482785600_deab050-B36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10815-014-0348-3","article-title":"To what extent does anti-mullerian hormone contribute to a better prediction of live birth after IVF?","volume":"32","author":"Rongieres","year":"2015","journal-title":"J Assist Reprod Genet"},{"key":"2021070807482785600_deab050-B37","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/humrep\/dev029","article-title":"Surgical diminished ovarian reserve after endometrioma cystectomy versus idiopathic DOR: comparison of in vitro fertilization outcome","volume":"30","author":"Roustan","year":"2015","journal-title":"Hum Reprod"},{"key":"2021070807482785600_deab050-B38","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3389\/fendo.2019.00409","article-title":"Cumulative live birth rates of good and low prognosis patients according to POSEIDON criteria: a single center analysis of 18,455 treatment cycles","volume":"10","author":"Shi","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2021070807482785600_deab050-B39","doi-asserted-by":"crossref","first-page":"e0121357","DOI":"10.1371\/journal.pone.0121357","article-title":"External validation and calibration of IVFpredict: a national prospective cohort study of 130,960 in vitro fertilisation cycles","volume":"10","author":"Smith","year":"2015","journal-title":"PLoS One"},{"key":"2021070807482785600_deab050-B89526825","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/biomet\/64.2.415","article-title":"A test for normality against symmetric alternatives","volume":"64","author":"Spiegelhalter","year":"1977","journal-title":"Biometrika"},{"key":"2021070807482785600_deab050-B40","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1126\/science.3287615","article-title":"Measuring the accuracy of diagnostic systems","volume":"240","author":"Swets","year":"1988","journal-title":"Science"},{"key":"2021070807482785600_deab050-B41","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0140-6736(96)05291-9","article-title":"Factors that affect outcome of in-vitro fertilisation treatment","volume":"348","author":"Templeton","year":"1996","journal-title":"The Lancet"},{"key":"2021070807482785600_deab050-B42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/352098","article-title":"Management of poor responders in IVF: Is there anything new?","volume":"2014","author":"Ubaldi","year":"2014","journal-title":"Biomed Res Int"},{"key":"2021070807482785600_deab050-B43","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00404-018-4987-y","article-title":"Bologna criteria are predictive for ovarian response and live birth in subsequent ovarian stimulation cycles","volume":"299","author":"Yakin","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"2021070807482785600_deab050-B44","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.rbmo.2016.02.013","article-title":"Younger poor ovarian response women achieved better pregnancy results in the first three IVF cycles","volume":"32","author":"Yang","year":"2016","journal-title":"Reprod Biomed Online"},{"key":"2021070807482785600_deab050-B11145","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2307\/2981577","article-title":"Test of significance for 2 \u00d7 2 contingency tables","volume":"147","author":"Yates","year":"1984","journal-title":"Journal of the Royal Statistical Society. Series A (General)"},{"key":"2021070807482785600_deab050-B45","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/humrep\/dex234","article-title":"The International Glossary on Infertility and Fertility Care, 2017","volume":"32","author":"Zegers-Hochschild","year":"2017","journal-title":"Hum Reprod"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/36\/6\/1600\/37948152\/deab050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/36\/6\/1600\/37948152\/deab050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T15:17:05Z","timestamp":1625757425000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/36\/6\/1600\/6226961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,16]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,4,16]]},"published-print":{"date-parts":[[2021,5,17]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deab050","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,4,16]]}}}